NCT06193434View on ClinicalTrials.gov

A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

August 20, 2025

Study Completion Date

August 20, 2025

Conditions
Healthy ParticipantsAtopic Dermatitis Patients
Interventions
DRUG

IBI356 for MAD

Receive IBI356 in a multiple dose.

DRUG

Dupilumab for MAD

Active comparator

DRUG

IBI356 for SAD

Receive IBI356 in a single dose.

DRUG

Placebo for SAD

Receive placebo in a single dose.

DRUG

Placebo for MAD

Receive placebo in a multiple dose.

Trial Locations (1)

200443

Shanghai Skin Disease Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06193434 - A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter